The regenerative therapy developer is based on research at University of Torino and has raised capital from returning backer V-Bio Ventures.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Synthetic biology-based vaccin developer Delonix Bioworks has completed a round co-led by Boehringer Ingelheim Venture Fund.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Transamerica and Scor-backed patient monitoring system developer has announced it has secured $25m in its seed round.

Technology-equipped healthcare membership service Forward Health has raised $225m from investors including SoftBank Vision Fund 2 at a valuation exceeding $1bn.

Sany Group and Fosun contributed to a $61.4m round for the third-party drug development services provider, which counts Jilin Aodong Medicine as an earlier backer.

Tencent and existing investor Nan Fung Life Sciences have helped the ophthalmology drug developer complete its series B round.

Cybrexa has secured $25m to progress a cancer treatment based on research at Yale University and University of Rhode Island.

The nanoemulsion delivery system developer raised series A funding from Haohai Biological alongside an $8m payment for the Chinese rights to its products.